osimertinib
astrazeneca
['lung', 'osimertinib']
breaking from asco: 3yrs #osimertinib improves survival in resected egfr+ lung cancer. will become new standard, no doubt. but, osimertinib works in advanced disease, and fewer than half the patients in control arm got subsequent osi. did withholding osi affect results? 
Professor of Oncology @Otago, working in research, policy, implementation, and clinical practice. Health is political! Views = own. He/him.